DOCSLIB.ORG

(12) Patent Application Publication (10) Pub. No.: US 2016/0250270 A1 Wendschuh Et Al

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(12) Patent Application Publication (10) Pub. No.: US 2016/0250270 A1 Wendschuh Et Al US 2016O250270A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2016/0250270 A1 Wendschuh et al. (43) Pub. Date: Sep. 1, 2016 (54) COMPOSITIONS COMPRISING Publication Classification COMBINATIONS OF PURIFED CANNABINOIDS, WITHAT LEAST ONE (51) Int. Cl. A61E36/85 (2006.01) FLAVONOID, TERPENE, OR MINERAL A63L/05 (2006.01) A63L/01 (2006.01) (71) Applicant: Ebbu, LLC, Evergreen, CO (US) A63L/045 (2006.01) A613 L/35 (2006.01) (72) Inventors: Michael Victor Wendschuh, Denver, A613 L/352 (2006.01) CO (US); Jonathan Michael Cooper, A63L/05 (2006.01) Denver, CO (US); Christopher Jarrad (52) U.S. Cl. Denicola, Denver, CO (US); Kurt Aron CPC ............. A61K 36/185 (2013.01); A61 K3I/352 Levy, Superior, CO (US); Jon Erik (2013.01); A61 K3I/05 (2013.01); A61 K Strickler, Denver, CO (US) 31/015 (2013.01); A61 K3I/045 (2013.01); A61 K31/35 (2013.01); A61 K3I/01 (2013.01) (57) ABSTRACT (21) Appl. No.: 15/055,499 Disclosed herein are new compositions having combinations of purified cannabinoids. One embodiment of this disclosure provides compositions having one or more purified cannab (22) Filed: Feb. 26, 2016 inoids in combination with a purified terpene. One embodi ment of this disclosure provides compositions having one or Related U.S. Application Data more purified cannabinoids in combination with a purified flavonoid. One embodiment of this disclosure provides com (60) Provisional application No. 62/126,365, filed on Feb. positions having one or more purified cannabinoids in com 27, 2015. bination with a purified mineral. US 2016/025O270 A1 Sep. 1, 2016 COMPOSITIONS COMPRISING have been no developments in combining purified cannab COMBINATIONS OF PURIFED inoids with purified terrenes, flavonoids, and/or minerals. CANNABINOIDS, WITHAT LEAST ONE 0009. There exists a need for compositions comprising FLAVONOID, TERPENE, OR MINERAL new combinations of purified cannabinoids. There also exists a particular need for compositions providing one or more CROSS-REFERENCE TO RELATED purified cannabinoids in combination with a purified terpene. APPLICATIONS Furthermore, there exists a need for compositions providing 0001. The present application claims priority on the basis one or more purified cannabinoids in combination with a of U.S. provisional application Ser. No. 62/126,365, filed purified flavonoid. Additionally, there exists a need for com Feb. 27, 2015, which is hereby incorporated by reference. positions providing one or more purified cannabinoids in combination with a purified mineral. TECHNICAL FIELD DETAILED DESCRIPTION 0002 This disclosure relates to the cannabis industry. In 0010 Disclosed herein are new compositions having com particular, the disclosure relates to compositions and formu binations of purified cannabinoids. One embodiment of this lations comprising purified cannabinoids, flavonoids, and/or disclosure provides compositions having one or more puri terpenes. fied cannabinoids in combination with a purified terpene. One BACKGROUND embodiment of this disclosure provides compositions having one or more purified cannabinoids in combination with a 0003 Cannabis is a genus of flowering plants that have purified flavonoid. One embodiment of this disclosure pro three different species: Cannabis sativa, Cannabis indica, vides compositions having one or more purified cannabinoids and Cannabis ruderalis. Cannabis has long been used for in combination with a purified mineral. hemp fiber, for seed and seed oils, for medicinal purposes, and 0011 Disclosed herein are compositions comprising: as a recreational drug. 0012 a first purified cannabinoid; and 0004 Cannabis is composed of at least 483 known chemi 0013 a compound chosen from a second purified can cal compounds, which include cannabinoids, terpenoids, fla nabinoid, a purified terpene, a purified flavonoid, and a vonoids, nitrogenous compounds, amino acids, proteins, gly purified mineral, coproteins, enzymes, Sugars and related compounds, 0.014 wherein the said composition is substantially free hydrocarbons, simple alcohols, aldehydes, ketones, simple from cellulose. acids, fatty acids, simple esters, lactones, Steroids, terpenes, 0015. As used herein, the term “purified’ means isolated non-cannabinoid phenols, vitamins, pigments, and elements. from the plant using chromatography, distillation, extrac These compounds are secreted on the glandular trichomes. tions, or similar technique resulting in a greater than 60% Cannabinoids are unique to the cannabis plant and there have purity. In some embodiments the “purified’ compositions been 100 cannabinoids that have been isolated as purified disclosed herein are greater than 70% purity. In some embodi (single) molecules. ments the “purified” compositions disclosed herein are 0005 Most extraction processes aim to extract cannab greater than 80% purity. In some embodiments the “purified’ inoids, particularly tetrahydrocannabinol (THC). THC has compositions disclosed herein are greater than 90% purity. many effects including pain relief, treating glaucoma, reliev 0016. Within the context of this disclosure, where a com ing nausea and Vomiting during cancer treatments. The latter pound comprises stereogenic centers, the term “purified’ is sold as the drug dronabinol. The brand name in the US is includes enantiomerically pure compositions and also mix Marinol. It is the pure isomer of THC, (-)-trans-A-tetrahy tures of enantiomers or isomers. drocannabinol which is man-made. 0017 Cannabinoids and other plant molecules may be 0006 Preparative gas chromatography has proven to be a extracted using various solvents and technologies including, suitable method for providing adequate pure samples of THC, but not limited to ethanol, butane, methane, carbon dioxide, Cannabidiol (CBD), and Cannabinol (CBN). There has been ice, water, Steam. Cannabinoids and other plant molecules difficulty in isolating pure cannabinoids in order to conduct may be extracted from plants bred to express desired cannab research. Cannabinoids can have synergistic or antagonistic inoid and/or terpene and/or flavonoid profiles for purity. Can effects on each other. Other methods of extraction include nabinoids and other molecules may be purified using Super butane hash oil (BHO) and supercritical carbon dioxide critical fluid (“SFC) extraction and similar technologies. In extraction. Cannabinoids are drawn out of the plant through one example, the process of crystallization involves placing Solvent (e.g., butane or carbon dioxide) extraction, which the compound of interest in a liquid and then cooling or produces a purified composition. adding participants to the solution which would lower the 0007. The resin glands, more commonly referred to as solubility of the compound of interest so that it forms crystals. kief, contain a high concentration of cannabinoids and terpe In this example, crystals are then separated from the liquid nes. The extraction process for kief involves placing the through filtration or centrifuge. whole plantina fine mesh screen shifter and gently shaking so 0018. As used herein, the term “cannabinoid’ means any that the kief falls through the screen away from the plant. The Substance that acts upon a cannabinoid receptor. For example kief is sometimes compressed into rounds known as hash or the term cannabinoid includes cannabinoid ligands such as hashish. agonists, partial agonists, inverse agonists, or antagonists, as 0008. Despite developments in isolating single molecules, demonstrated by binding studies and functional assays. In no work has been done in formulating compositions having many examples, a cannabinoid can be identified because its particular combinations of the purified compounds. There has chemical name will include the text string “cannabi in the been no work developing compounds having repeatable, name. Within the context of this application, where reference dependable ratios of purified molecules. In particular, there is made to a particular cannabinoid, each of the acid and/or US 2016/025O270 A1 Sep. 1, 2016 decarboxylated forms are contemplated as both single mol tan, Methyl Mercaptan, Furfuryl Mercaptan, Ethylene ecules and mixtures. Examples of cannabinoids within the Mercaptan, Propyl Mercaptan, Thenyl Mercaptan, Methyl context of this disclosure include compounds belonging to Salicylate, Methylbutenol, Methyl-2-Methylvalerate, Methyl any of the following classes of molecules, their derivatives, Thiobutyrate, Myrcene (B-Myrcene), Y-Muurolene, Nepeta salts, or analogs: Tetrahydrocannabinol (THC), Tetrahydro lactone, Nerol, Nerolidol, Neryl acetate. Nonanaldehyde, cannabivarin (THCV), Cannabichromene (CBC), Cannab Nonanoic Acid, Ocimene, Octanal, Octanoic Acid, ichromanon (CBCN), Cannabidiol (CBD), Cannabielsoin P-cymene, Penty1 butyrate, Phelandrene, Phenylacetalde (CBE), Cannabidivarin (CBDV), Cannbifuran (CBF), Can hyde, Phenylethanethiol, Phenylacetic Acid, Phytol, Pinene, nabigerol (CBG), Cannabicyclol (CBL), Cannabinol (CBN), B-Pinene, Propanethiol, Pristimerin, Pulegone, Quercetin, Cannabinodiol (CBND), Cannabitriol (CBT), Cannabivarin Retinol, Rutin, Sabinene, Sabinene Hydrate, cis-Sabinene (CBV), and Isocanabinoids. Hydrate, trans-Sabinene Hydrate, Safranal, C-Selinene, 0019. As used herein, the term “terpene' means an organic C-Sinensal, B-Sinensal, B-Sitosterol, Squalene, Taxadiene, compound built on an isoprenoid structural scaffold or pro Terpin hydrate, Terpineol, Terpine-4-ol, C.-Terpinene, Y-Ter duced by combining isoprene units. Often, terpene molecules pinene, Terpinolene. Thiophenol.
Load more

Recommended publications
  • INVESTIGATION of NATURAL PRODUCT SCAFFOLDS for the DEVELOPMENT of OPIOID RECEPTOR LIGANDS by Katherine M
    INVESTIGATION OF NATURAL PRODUCT SCAFFOLDS FOR THE DEVELOPMENT OF OPIOID RECEPTOR LIGANDS By Katherine M. Prevatt-Smith Submitted to the graduate degree program in Medicinal Chemistry and the Graduate Faculty of the University of Kansas in partial fulfillment of the requirements for the degree of Doctor of Philosophy. _________________________________ Chairperson: Dr. Thomas E. Prisinzano _________________________________ Dr. Brian S. J. Blagg _________________________________ Dr. Michael F. Rafferty _________________________________ Dr. Paul R. Hanson _________________________________ Dr. Susan M. Lunte Date Defended: July 18, 2012 The Dissertation Committee for Katherine M. Prevatt-Smith certifies that this is the approved version of the following dissertation: INVESTIGATION OF NATURAL PRODUCT SCAFFOLDS FOR THE DEVELOPMENT OF OPIOID RECEPTOR LIGANDS _________________________________ Chairperson: Dr. Thomas E. Prisinzano Date approved: July 18, 2012 ii ABSTRACT Kappa opioid (KOP) receptors have been suggested as an alternative target to the mu opioid (MOP) receptor for the treatment of pain because KOP activation is associated with fewer negative side-effects (respiratory depression, constipation, tolerance, and dependence). The KOP receptor has also been implicated in several abuse-related effects in the central nervous system (CNS). KOP ligands have been investigated as pharmacotherapies for drug abuse; KOP agonists have been shown to modulate dopamine concentrations in the CNS as well as attenuate the self-administration of cocaine in a variety of species, and KOP antagonists have potential in the treatment of relapse. One drawback of current opioid ligand investigation is that many compounds are based on the morphine scaffold and thus have similar properties, both positive and negative, to the parent molecule. Thus there is increasing need to discover new chemical scaffolds with opioid receptor activity.
    [Show full text]
  • Opportunities and Pharmacotherapeutic Perspectives
    biomolecules Review Anticoronavirus and Immunomodulatory Phenolic Compounds: Opportunities and Pharmacotherapeutic Perspectives Naiara Naiana Dejani 1 , Hatem A. Elshabrawy 2 , Carlos da Silva Maia Bezerra Filho 3,4 and Damião Pergentino de Sousa 3,4,* 1 Department of Physiology and Pathology, Federal University of Paraíba, João Pessoa 58051-900, Brazil; [email protected] 2 Department of Molecular and Cellular Biology, College of Osteopathic Medicine, Sam Houston State University, Conroe, TX 77304, USA; [email protected] 3 Department of Pharmaceutical Sciences, Federal University of Paraíba, João Pessoa 58051-900, Brazil; [email protected] 4 Postgraduate Program in Bioactive Natural and Synthetic Products, Federal University of Paraíba, João Pessoa 58051-900, Brazil * Correspondence: [email protected]; Tel.: +55-83-3216-7347 Abstract: In 2019, COVID-19 emerged as a severe respiratory disease that is caused by the novel coronavirus, Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2). The disease has been associated with high mortality rate, especially in patients with comorbidities such as diabetes, cardiovascular and kidney diseases. This could be attributed to dysregulated immune responses and severe systemic inflammation in COVID-19 patients. The use of effective antiviral drugs against SARS-CoV-2 and modulation of the immune responses could be a potential therapeutic strategy for Citation: Dejani, N.N.; Elshabrawy, COVID-19. Studies have shown that natural phenolic compounds have several pharmacological H.A.; Bezerra Filho, C.d.S.M.; properties, including anticoronavirus and immunomodulatory activities. Therefore, this review de Sousa, D.P. Anticoronavirus and discusses the dual action of these natural products from the perspective of applicability at COVID-19.
    [Show full text]
  • Yangonin Blocks Tumor Necrosis Factor-Α–Induced Nuclear Factor-Κb–Dependent Transcription by Inhibiting the Transactivation Potential of the Rela/P65 Subunit
    J Pharmacol Sci 118, 447 – 454 (2012) Journal of Pharmacological Sciences © The Japanese Pharmacological Society Full Paper Yangonin Blocks Tumor Necrosis Factor-α–Induced Nuclear Factor-κB–Dependent Transcription by Inhibiting the Transactivation Potential of the RelA/p65 Subunit Juan Ma1,†, He Liang1,†, Hong Ri Jin2, Nguyen Tien Dat3, Shan Yu Zhang1, Ying Zi Jiang1, Ji Xing Nan1, Donghao Li1, Xue Wu1, Jung Joon Lee1,2,*a, and Xuejun Jin1,*b 1Key Laboratory of Natural Resources of Changbai Mountain & Functional Molecules, Yanbian University, Ministry of Education, Yanji Jilin 133002, China 2Center for Molecular Cancer Research, Korea Research Institute of Bioscience and Biotechnology, Ochang, Chungbuk 363-883, Republic of Korea 3Institute of Marine Biochemistry, Vietnam Academy of Science and Technology, 18-Hoang Quoc Viet, Hanoi, Vietnam Received November 13, 2011; Accepted January 23, 2012 Abstract. The nuclear factor-κB (NF-κB) transcription factors control many physiological pro- cesses including inflammation, immunity, and apoptosis. In our search for NF-κB inhibitors from natural resources, we identified yangonin from Piper methysticum as an inhibitor of NF-κB activa- tion. In the present study, we demonstrate that yangonin potently inhibits NF-κB activation through suppression of the transcriptional activity of the RelA/p65 subunit of NF-κB. This compound sig- nificantly inhibited the induced expression of the NF-κB-reporter gene. However, this compound did not interfere with tumor necrosis factor-α (TNF-α)-induced inhibitor of κBα (IκBα) degrada- tion, p65 nuclear translocation, and DNA-binding activity of NF-κB. Further analysis revealed that yangonin inhibited not only the induced NF-κB activation by overexpression of RelA/p65, but also transactivation activity of RelA/p65.
    [Show full text]
  • A Review on Amentoflavone
    Indo American Journal of Pharmaceutical Research, 2017 ISSN NO: 2231-6876 A REVIEW ON AMENTOFLAVONE * Aroosa Siddique , Madiha Jabeen, Osman Ahmed Department of Pharmaceutical Chemistry, Deccan School of Pharmacy, Hyderabad, T.S. ARTICLE INFO ABSTRACT Article history Amentoflavone, is a bioflavonoid constituent of some of flora which includes ginkgo biloba, Received 06/02/2017 hypericum perforatum. It can have interaction with many medicinal drugs by using being a Available online potent inhibitor of CYP3A4 and CYP2C9 which are enzymes chargeable for the metabolism 28/02/2017 of some drugs in the body. Flavonoids exhibit a extensive variety of activities including antioxidant, antiviral, Antibacterial and anticancer pastime. As formerly we showed that Keywords amentoflavone is an activator of hPPARγ. Human PPARγ (hPPARγ) regulates the Amentoflavone, proliferation, apoptosis, and various human most cancers cells. Activated hPPARγ has both Flavonoid, tumor suppressor and tumor promoter. To affirm the mechanism of motion of amentoflavone Synthetic, in most cancers cells, we analyzed whether or not amentoflavone remedy affects the RSV, Hpparγ, appearance of hPPARy the use of opposite transcription polymerase chain response and CYP3A4 & CYP2C9. actual time quantitive PCR. Amentoflavone is synthesized with the aid of way of three techniques i.e natural, semi synthetic and synthetic methods. Among this synthetic method is widely used industrially. Application of the Suzuki-Miyaura response within the synthesis of flavonoids, is of vital magnificence of natural merchandise, is studied. Amentoflavone and three different flavonoids were separated from the ethanol extract of Selaginella sinensis. Amentoflavone show strong antiviral pastime in opposition to respiratory syncytial virus (RSV). The cytotoxic interest of amentoflavone is examined against 5 human most cancers cell strains (MCF-7, A549, HeLa, MDA-MB231, and PC3) treating with tetrazolium- primarily based colorimetric MTT assay.
    [Show full text]
  • Herbal Insomnia Medications That Target Gabaergic Systems: a Review of the Psychopharmacological Evidence
    Send Orders for Reprints to [email protected] Current Neuropharmacology, 2014, 12, 000-000 1 Herbal Insomnia Medications that Target GABAergic Systems: A Review of the Psychopharmacological Evidence Yuan Shia, Jing-Wen Donga, Jiang-He Zhaob, Li-Na Tanga and Jian-Jun Zhanga,* aState Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, P.R. China; bDepartment of Pharmacology, School of Marine, Shandong University, Weihai, P.R. China Abstract: Insomnia is a common sleep disorder which is prevalent in women and the elderly. Current insomnia drugs mainly target the -aminobutyric acid (GABA) receptor, melatonin receptor, histamine receptor, orexin, and serotonin receptor. GABAA receptor modulators are ordinarily used to manage insomnia, but they are known to affect sleep maintenance, including residual effects, tolerance, and dependence. In an effort to discover new drugs that relieve insomnia symptoms while avoiding side effects, numerous studies focusing on the neurotransmitter GABA and herbal medicines have been conducted. Traditional herbal medicines, such as Piper methysticum and the seed of Zizyphus jujuba Mill var. spinosa, have been widely reported to improve sleep and other mental disorders. These herbal medicines have been applied for many years in folk medicine, and extracts of these medicines have been used to study their pharmacological actions and mechanisms. Although effective and relatively safe, natural plant products have some side effects, such as hepatotoxicity and skin reactions effects of Piper methysticum. In addition, there are insufficient evidences to certify the safety of most traditional herbal medicine. In this review, we provide an overview of the current state of knowledge regarding a variety of natural plant products that are commonly used to treat insomnia to facilitate future studies.
    [Show full text]
  • Herbal Medicines in Pregnancy and Lactation : an Evidence-Based
    00 Prelims 1410 10/25/05 2:13 PM Page i Herbal Medicines in Pregnancy and Lactation An Evidence-Based Approach Edward Mills DPh MSc (Oxon) Director, Division of Clinical Epidemiology Canadian College of Naturopathic Medicine North York, Ontario, Canada Jean-Jacques Duguoa MSc (cand.) ND Naturopathic Doctor Toronto Western Hospital Assistant Professor Division of Clinical Epidemiology Canadian College of Naturopathic Medicine North York, Ontario, Canada Dan Perri BScPharm MD MSc Clinical Pharmacology Fellow University of Toronto Toronto, Ontario, Canada Gideon Koren MD FACMT FRCP Director of Motherisk Professor of Medicine, Pediatrics and Pharmacology University of Toronto Toronto, Ontario, Canada With a contribution from Paul Richard Saunders PhD ND DHANP 00 Prelims 1410 10/25/05 2:13 PM Page ii © 2006 Taylor & Francis Medical, an imprint of the Taylor & Francis Group First published in the United Kingdom in 2006 by Taylor & Francis Medical, an imprint of the Taylor & Francis Group, 2 Park Square, Milton Park, Abingdon, Oxon OX14 4RN Tel.: ϩ44 (0)20 7017 6000 Fax.: ϩ44 (0)20 7017 6699 E-mail: [email protected] Website: www.tandf.co.uk/medicine All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or trans- mitted, in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise, without the prior permission of the publisher or in accordance with the provisions of the Copyright, Designs and Patents Act 1988 or under the terms of any licence permitting limited copying issued by the Copyright Licensing Agency, 90 Tottenham Court Road, London W1P 0LP.
    [Show full text]
  • Medicinal Plants As Sources of Active Molecules Against COVID-19
    REVIEW published: 07 August 2020 doi: 10.3389/fphar.2020.01189 Medicinal Plants as Sources of Active Molecules Against COVID-19 Bachir Benarba 1* and Atanasio Pandiella 2 1 Laboratory Research on Biological Systems and Geomatics, Faculty of Nature and Life Sciences, University of Mascara, Mascara, Algeria, 2 Instituto de Biolog´ıa Molecular y Celular del Ca´ ncer, CSIC-IBSAL-Universidad de Salamanca, Salamanca, Spain The Severe Acute Respiratory Syndrome-related Coronavirus 2 (SARS-CoV-2) or novel coronavirus (COVID-19) infection has been declared world pandemic causing a worrisome number of deaths, especially among vulnerable citizens, in 209 countries around the world. Although several therapeutic molecules are being tested, no effective vaccines or specific treatments have been developed. Since the COVID-19 outbreak, different traditional herbal medicines with promising results have been used alone or in combination with conventional drugs to treat infected patients. Here, we review the recent findings regarding the use of natural products to prevent or treat COVID-19 infection. Furthermore, the mechanisms responsible for this preventive or therapeutic effect are discussed. We conducted literature research using PubMed, Google Scholar, Scopus, and WHO website. Dissertations and theses were not considered. Only the situation Edited by: Michael Heinrich, reports edited by the WHO were included. The different herbal products (extracts) and UCL School of Pharmacy, purified molecules may exert their anti-SARS-CoV-2 actions by direct inhibition of the virus United Kingdom replication or entry. Interestingly, some products may block the ACE-2 receptor or the Reviewed by: Ulrike Grienke, serine protease TMPRRS2 required by SARS-CoV-2 to infect human cells.
    [Show full text]
  • St. John's Wort 2018
    ONLINE SERIES MONOGRAPHS The Scientific Foundation for Herbal Medicinal Products Hyperici herba St. John's Wort 2018 www.escop.com The Scientific Foundation for Herbal Medicinal Products HYPERICI HERBA St. John's Wort 2018 ESCOP Monographs were first published in loose-leaf form progressively from 1996 to 1999 as Fascicules 1-6, each of 10 monographs © ESCOP 1996, 1997, 1999 Second Edition, completely revised and expanded © ESCOP 2003 Second Edition, Supplement 2009 © ESCOP 2009 ONLINE SERIES ISBN 978-1-901964-61-5 Hyperici herba - St. John's Wort © ESCOP 2018 Published by the European Scientific Cooperative on Phytotherapy (ESCOP) Notaries House, Chapel Street, Exeter EX1 1EZ, United Kingdom www.escop.com All rights reserved Except for the purposes of private study, research, criticism or review no part of this text may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, without the written permission of the publisher. Important Note: Medical knowledge is ever-changing. As new research and clinical experience broaden our knowledge, changes in treatment may be required. In their efforts to provide information on the efficacy and safety of herbal drugs and herbal preparations, presented as a substantial overview together with summaries of relevant data, the authors of the material herein have consulted comprehensive sources believed to be reliable. However, in view of the possibility of human error by the authors or publisher of the work herein, or changes in medical knowledge, neither the authors nor the publisher, nor any other party involved in the preparation of this work, warrants that the information contained herein is in every respect accurate or complete, and they are not responsible for any errors or omissions or for results obtained by the use of such information.
    [Show full text]
  • Assessment Report on Hypericum Perforatum L., Herba
    European Medicines Agency Evaluation of Medicines for Human Use London, 12 November 2009 Doc. Ref.: EMA/HMPC/101303/2008 COMMITTEE ON HERBAL MEDICINAL PRODUCTS (HMPC) ASSESSMENT REPORT ON HYPERICUM PERFORATUM L., HERBA 7 Westferry Circus, Canary Wharf, London, E14 4HB, UK Tel. (44-20) 74 18 84 00 Fax (44-20) 75 23 70 51 E-mail: [email protected] http://www.emea.europa.eu © European Medicines Agency, 2009. Reproduction is authorised provided the source is acknowledged TABLE OF CONTENTS I. REGULATORY STATUS OVERVIEW...................................................................................4 II. ASSESSMENT REPORT............................................................................................................5 II.1 INTRODUCTION..........................................................................................................................6 II.1.1 Description of the herbal substance(s), herbal preparation(s) or combinations thereof 6 II.1.1.1 Herbal substance:........................................................................................................ 6 II.1.1.2 Herbal preparation(s): ................................................................................................ 7 II.1.1.3 Combinations of herbal substance(s) and/or herbal preparation(s)........................... 9 Not applicable. ................................................................................................................................9 II.1.1.4 Vitamin(s) ...................................................................................................................
    [Show full text]
  • Keynotes of the Homoeopathic Materia Medica Dr. Adolph VON
    KKeeyynnootteess ooff TThhee HHoommooeeooppaatthhiicc MMaatteerriiaa MMeeddiiccaa DDrr.. AAddoollpphh VVOONN LLIIPPPPEE Aconitum Napellus. Agaricus Muscarius. Agnus Castus. Allium Cepa. Aloe. Alumina. Ambra Grisea. Ammonium Carbonicum. Ammonium Muriaticum. Anacardium. Angustura. Antimonium Crudum. Antimonium Tartaricum Apis Mellifica. Argentum Metallicum. Arnica Montana. Arsenic Album. Arsenic Metallicum. Asafoetida. Asarum Europaeum. Aurum Metallicum. Baryta Carbonica. Belladonna. Bismuth. Borax. Bovista. Bromium. Bryonia Alba. Caladium Seguinum. Calcarea Ostrearum. Camphora. Cannabis Sativa. Cantharides. Capsicum. Carbo Animalis. Carbo Vegetablis. Cascarilla. Castoreum. Causticum. Chamomilla. Chelidonium Majus. Cicuta Virosa. China. Cina. Cinnamonum. Cinnabaris. Clematis Erecta. Cocculus. Coffee Cruda. Colchicum. Colocynthis. Conium Maculatum. Corallium Rubrum. Crocus Sativus. Croton Tiglium. Cuprum Metallicum. Cyclamen. Daphne Mezereum. Digitalis Purpurea. Drosera. Dulcamara. Euphorbia. Euphrasia. Ferrum Metallicum. Graphites. Guajacum. Helleborus Niger. Hepar Sulphuris Calcareum. Hyoscyamus Niger. Ignatia Amara. Iodum. Ipecacuanha. Kali Carbonicum. Kali Nitrium. Laurocerasus. Ledum Palustre. Lycopodium Clavatum. Magnesia Carbonica. Manganum. Menyanthes. Mercurius Sublimatus. Mercurius Solubilis Hahnemanni. Mezereum Daphne. Moschus. Muraticum Acidum. Natrum Carbonicum. Natrum Muriaticum. Nitric Acidum. Nux Moschata. Oleander. Opium. Paris Quadrifolia. Phosphoric acid. Phosphorus. Platina. Plumbum. Ranunculus Bulbosus. Ranunculus Scleratus.
    [Show full text]
  • Thesis-1966D-R342b.Pdf
    I I THE BIOSYNTHESIS OF NEPETALACTONE By FREDERICK EUGENE REGNIER 01 Bachelor of Science Peru State College Peru, Nebraska 1960 Submitted to the Faculty of the Graduate School of the Oklahoma State University in partial fulfillment of the requirements for the degree of DOCTOR OF PHILOSOPHY May, 1966 THE BIOSYNTHESIS OF NEPETALACTONE Thesis Approved: l/ ~;==chool ii ACKNOWLEDGEMENTS The author wishes to express his gratitude and appreciation to: Dr. G. R. Waller and Dr. E. J. Eisenbraun for their guidance, counsel and assistance during the course of this study. Dr. E. C. Horning for placing the combined mass spectrometer-gas chromatograph at my disposal. Mr. Sten Wikstrom for his technical assistance in operating the mass spectrometer. Dr. M. H. Brooks for her assistance in the histological studies. Dr. W. R. Kays for providing plant material. Dr. V. T. Waterfall for making botanical classification. Dr. H. Auda and Mr. G. V. Odell for their suggestions and technical assistance. Mrs. Linda M. Regnier for her assistance and encouragement during this study. iii TABLE OF CONTENTS Chapter Page I. INTRODUCTION 1 II. LITERATURE REVIEW 3 III. COMPOSITION OF THE ESSENTIAL OIL OF NEPETA cataria L.. 13 IV. THE DISTRIBUTION AND ANALYSIS OF NEPETALACTONE ISOMERS FROM DIFFERENT NEPETA SPECIES 54 V. THE BIOSYNTHESIS OF NEPETALACTONE 70 VI. SUMMARY 103 BIBLIOGRAPHY 105 iv LIST OF TABLES Table Page CHAPTER III I. Tabulation of the Intense Ions in the Spectra of the Compounds in Fraction A 21+ II. Tabulation of the Intense Ions in the Spectra of the Compounds in Fraction B 27 III. Tabulation of the Intense Ions in the Spectrum of Sample c4 .
    [Show full text]
  • Dr. Duke's Phytochemical and Ethnobotanical Databases List of Chemicals for Kidney Stones
    Dr.
    [Show full text]